Similar to the rest of the India, the pharmaceutical industry here is rapidly transforming. By 2010, revenue for the industry is estimated to be more than $10 Billion USD, nearly double the revenue in 2005. The transformation includes not only growth in quantity, but improvement in quality as well; by 2006, India had 75 FDA approved plants, compared to only 55 in Italy and 27 in China. While the United States currently dominates the market for High-Quality APIs, both India and China are rapidly catching up and may soon surpass the United States, according to Gurpreet Sandhu, head of API business, Ranbaxy Laboratories. Today he will deliver a speech entitled “API sourcing strategies—India” in the “CPhI China 2009 International Forum”. According to Newport Horizon Premium, the number of future corporate groups available to produce High-Quality APIs is 76 in India, compared to zero in the USA and four in Brazil. In combination with advancements in technology and the quality yet inexpensive work-force, this has created boundless opportunities for outsourcing. While China was receiving most of the Pharmaceutical outsourcing as of 2007, there are many reasons to believe India will be a future destination of pharmaceutical corporations looking to acquire good yet inexpensive talent, high quality standards, and excellent manufacturing facilities. In 2008 alone, a multitude of Fortune 500 companies entered the pharmaceutical market in India -- we can only expect that trend to continue.